Brian Lloyd Acquires 2,000 Shares of Merit Medical Systems (NASDAQ:MMSI) Stock

Posted by Brian Himes on May 11th, 2026

Merit Medical Systems, Inc. (NASDAQ:MMSI – Get Free Report) insider Brian Lloyd bought 2,000 shares of the company’s stock in a transaction on Thursday, May 7th. The shares were acquired at an average price of $62.62 per share, for a total transaction of $125,240.00. Following the completion of the acquisition, the insider owned 2,000 shares in the company, valued at $125,240. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Merit Medical Systems Stock Down 0.2%

Merit Medical Systems stock traded down $0.13 during midday trading on Monday, hitting $61.15. 226,354 shares of the company’s stock were exchanged, compared to its average volume of 784,682. Merit Medical Systems, Inc. has a 12 month low of $59.74 and a 12 month high of $100.19. The company has a market cap of $3.65 billion, a PE ratio of 26.47, a P/E/G ratio of 1.91 and a beta of 0.58. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.46 and a current ratio of 5.08. The firm has a 50-day moving average of $69.44 and a two-hundred day moving average of $79.36.

Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.10. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. The business had revenue of $381.88 million for the quarter, compared to analysts’ expectations of $377.59 million. During the same period last year, the business earned $0.86 EPS. The company’s revenue was up 7.4% compared to the same quarter last year. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. As a group, analysts expect that Merit Medical Systems, Inc. will post 3.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Merit Medical Systems

Several hedge funds and other institutional investors have recently modified their holdings of MMSI. AQR Capital Management LLC raised its position in shares of Merit Medical Systems by 7.3% in the 1st quarter. AQR Capital Management LLC now owns 16,361 shares of the medical instruments supplier’s stock valued at $1,730,000 after purchasing an additional 1,114 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Merit Medical Systems by 16.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 719,313 shares of the medical instruments supplier’s stock valued at $76,039,000 after acquiring an additional 103,878 shares during the period. EverSource Wealth Advisors LLC lifted its stake in Merit Medical Systems by 745.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 922 shares of the medical instruments supplier’s stock valued at $86,000 after acquiring an additional 813 shares during the period. First Trust Advisors LP lifted its stake in Merit Medical Systems by 24.8% during the 2nd quarter. First Trust Advisors LP now owns 59,215 shares of the medical instruments supplier’s stock valued at $5,535,000 after acquiring an additional 11,770 shares during the period. Finally, Cerity Partners LLC lifted its stake in Merit Medical Systems by 9.1% during the 2nd quarter. Cerity Partners LLC now owns 3,019 shares of the medical instruments supplier’s stock valued at $282,000 after acquiring an additional 251 shares during the period. 99.66% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on MMSI shares. BTIG Research started coverage on shares of Merit Medical Systems in a report on Friday, February 6th. They issued a “buy” rating and a $107.00 price target on the stock. Robert W. Baird set a $83.00 price target on shares of Merit Medical Systems in a report on Friday, May 1st. JPMorgan Chase & Co. decreased their price objective on shares of Merit Medical Systems from $95.00 to $77.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Barrington Research decreased their price objective on shares of Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating for the company in a research report on Monday, April 20th. Finally, Compass Point set a $107.00 price objective on shares of Merit Medical Systems in a research report on Monday, April 20th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $92.80.

Check Out Our Latest Research Report on MMSI

Merit Medical Systems Company Profile

(Get Free Report)

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.